Examining the evolving utility of 18FDG-PET/CT in breast cancer recurrence

Djassemi, Navid; Rampey, Shilpa; Motiani, Juhi

doi:10.21037/tcr.2019.07.07

Cited by 4 publications

(3 citation statements)

References 29 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of early BC patients undergo local excision surgery and postoperative radiotherapy, with a 5-year relative survival rate of approximately 98% for those diagnosed with localized disease. While locoregional recurrence carries a poor prognosis, early detection and staging of recurrence can improve survival [ 49 ].…”

Section: Introductionmentioning

confidence: 99%

PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives

Katal,

McKay,

Taubman

2024

JCM

View full text Add to dashboard Cite

Positron emission tomography (PET) plays a crucial role in breast cancer management. This review addresses the role of PET imaging in breast cancer care. We focus primarily on the utility of 18F-fluorodeoxyglucose (FDG) PET in staging, recurrence detection, and treatment response evaluation. Furthermore, we delve into the growing interest in precision therapy and the development of novel radiopharmaceuticals targeting tumor biology. This includes discussing the potential of PET/MRI and artificial intelligence in breast cancer imaging, offering insights into improved diagnostic accuracy and personalized treatment approaches.

show abstract

Section: Introductionmentioning

confidence: 99%

PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives

Katal,

McKay,

Taubman

2024

JCM

View full text Add to dashboard Cite

show abstract

“…Positron emission tomography (PET) images of the radiotracer 2-deoxy-2-[ 18 F]-fluoro-D-glucose (FDG) are used widely for tumour staging and assessment of treatment response [ 1 ]. In routine practice single static FDG-PET images are collected around an hour after tracer injection.…”

Section: Introductionmentioning

confidence: 99%

Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism

et al. 2022

View full text Add to dashboard Cite

Background PET imaging of 18F-fluorodeoxygucose (FDG) is used widely for tumour staging and assessment of treatment response, but the biology associated with FDG uptake is still not fully elucidated. We therefore carried out gene set enrichment analyses (GSEA) of RNA sequencing data to find KEGG pathways associated with FDG uptake in primary breast cancers. Methods Pre-treatment data were analysed from a window-of-opportunity study in which 30 patients underwent static and dynamic FDG-PET and tumour biopsy. Kinetic models were fitted to dynamic images, and GSEA was performed for enrichment scores reflecting Pearson and Spearman coefficients of correlations between gene expression and imaging. Results A total of 38 pathways were associated with kinetic model flux-constants or static measures of FDG uptake, all positively. The associated pathways included glycolysis/gluconeogenesis (‘GLYC-GLUC’) which mediates FDG uptake and was associated with model flux-constants but not with static uptake measures, and 28 pathways related to immune-response or inflammation. More pathways, 32, were associated with the flux-constant K of the simple Patlak model than with any other imaging index. Numbers of pathways categorised as being associated with individual micro-parameters of the kinetic models were substantially fewer than numbers associated with flux-constants, and lay around levels expected by chance. Conclusions In pre-treatment images GLYC-GLUC was associated with FDG kinetic flux-constants including Patlak K, but not with static uptake measures. Immune-related pathways were associated with flux-constants and static uptake. Patlak K was associated with more pathways than were the flux-constants of more complex kinetic models. On the basis of these results Patlak analysis of dynamic FDG-PET scans is advantageous, compared to other kinetic analyses or static imaging, in studies seeking to infer tumour-to-tumour differences in biology from differences in imaging. Trial registration NCT01266486, December 24th 2010.

show abstract

“…Djassemi N. et al reported that elevated serum tumor markers can be useful prognostic markers of recurrence in asymptomatic breast cancer patients[4]. In another review, high levels of CA 15.3 marker indicate, almost certainly, the presence of metastatic disease[5].…”

mentioning

confidence: 99%

Scoping Review: Emerging (Bio)markers for the Early Detection of Breast Cancer Recurrence

Sallauka,

Horvat,

Ravnik

et al. 2024

Preprint

View full text Add to dashboard Cite

Background The aim of this study is to gain a comprehensive understanding of the latest advancements in breast cancer recurrence markers, with the aim of identifying minimally invasive or minimally intrusive markers as necessary approach for screening for breast cancer recurrence. Methods We followed PRISMA guidelines, systematically searching Web of Science, Scopus, and PubMed from 2010 to December 2023 for secondary papers on breast cancer markers of recurrence. Keywords used to search the databases include but are not limited to: “breast cancer recurrence”, “markers”, “radiology”, “pathology”, “clinical features”. The search was limited to English language. Selected papers underwent screening process according to inclusion/exclusion criteria, and data extraction included publication details, markers, marker modality, among others. Results The number of papers considered for this review was 1,138. After two phases of screening process, a total number of 28 reviews were included in this scoping review. We have categorized markers into radiological, clinical, and histopathological types. Among the most relevant clinical markers correlated with breast cancer (BC) recurrence are clinical stage, carcinoembryogenic antigen (CEA), and cancer antigen 15.3 (CA 15.3). We have also identified that the following radiological markers are the most mentioned markers associated with recurrence: mammographic density (MD), tumor heterogeneity, most enhancing tumor volume (METV), radiomic features, and more. Furthermore, we identified nuclear grade, microenvironment heterogeneity, estrogen receptor (ER), androgen receptor (AR), human epidermal growth factor receptor 2 (HER2), Ki-67 antigen, as the most significant histopathological markers of breast cancer recurrence. Conclusion This review identified promising markers for breast cancer recurrence in three categories: clinical, radiological and histopathological. General practitioners can leverage these insights for enhanced pre-screening, aiding in earlier detection and intervention, thus improving patient outcomes. Unclear cut-off values and disagreement on their use remain obstacles.

show abstract

Examining the evolving utility of 18FDG-PET/CT in breast cancer recurrence

Cited by 4 publications

References 29 publications

PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives

PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives

Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism

Scoping Review: Emerging (Bio)markers for the Early Detection of Breast Cancer Recurrence

Contact Info

Product

Resources

About